Sibylla Biotech developed small molecule folding interfering degraders (FIDs) that can address a range of therapeutic areas.
Sibylla Biotech has raised $23.0M in total funding. The most recent round was Series A. The last funding was announced in October 2022.
Sibylla Biotech's investors include CDP Venture Capital, VI Partners, Vertis, Indaco Venture Partners, Claris Ventures.
Sibylla Biotech is headquartered in Trento, Italy.
Sibylla Biotech developed small molecule folding interfering degraders (FIDs) that can address a range of therapeutic areas.
Sibylla Biotech is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Sibylla Biotech — Funding & Investors." VCBacked, October 4, 2022, https://www.vcbacked.co/company/sibylla-biotech. Accessed July 19, 2026.
VCBacked. (2022). Sibylla Biotech — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/sibylla-biotech
{{cite web |title=Sibylla Biotech — Funding & Investors |url=https://www.vcbacked.co/company/sibylla-biotech |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated